332 related articles for article (PubMed ID: 17223435)
1. An orwellian discourse on the meaning and measurement of noninferiority.
Diamond GA; Kaul S
Am J Cardiol; 2007 Jan; 99(2):284-7. PubMed ID: 17223435
[TBL] [Abstract][Full Text] [Related]
2. Making sense of noninferiority: a clinical and statistical perspective on its application to cardiovascular clinical trials.
Kaul S; Diamond GA
Prog Cardiovasc Dis; 2007; 49(4):284-99. PubMed ID: 17185116
[TBL] [Abstract][Full Text] [Related]
3. Prior convictions: Bayesian approaches to the analysis and interpretation of clinical megatrials.
Diamond GA; Kaul S
J Am Coll Cardiol; 2004 Jun; 43(11):1929-39. PubMed ID: 15172393
[TBL] [Abstract][Full Text] [Related]
4. Randomization as a basis for inference in noninferiority trials.
Wiens BL
Pharm Stat; 2006; 5(4):265-71. PubMed ID: 17128425
[TBL] [Abstract][Full Text] [Related]
5. Likelihood ratio and a Bayesian approach were superior to standard noninferiority analysis when the noninferiority margin varied with the control event rate.
Kim MY; Xue X
J Clin Epidemiol; 2004 Dec; 57(12):1253-61. PubMed ID: 15617951
[TBL] [Abstract][Full Text] [Related]
6. A more powerful exact test of noninferiority from binary matched-pairs data.
Lloyd CJ; Moldovan MV
Stat Med; 2008 Aug; 27(18):3540-9. PubMed ID: 18314932
[TBL] [Abstract][Full Text] [Related]
7. Bayesian approach to noninferiority trials for proportions.
Gamalo MA; Wu R; Tiwari RC
J Biopharm Stat; 2011 Sep; 21(5):902-19. PubMed ID: 21830922
[TBL] [Abstract][Full Text] [Related]
8. Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials.
Wijeysundera DN; Austin PC; Hux JE; Beattie WS; Laupacis A
J Clin Epidemiol; 2009 Jan; 62(1):13-21.e5. PubMed ID: 18947971
[TBL] [Abstract][Full Text] [Related]
9. Interpretation and inference in noninferiority randomized controlled trials in drug research.
Wangge G; Klungel OH; Roes KC; de Boer A; Hoes AW; Knol MJ
Clin Pharmacol Ther; 2010 Sep; 88(3):420-3. PubMed ID: 20668448
[TBL] [Abstract][Full Text] [Related]
10. Bayesian inference for randomized clinical trials with treatment failures.
Shaffer ML; Chinchilli VM
Stat Med; 2004 Apr; 23(8):1215-28. PubMed ID: 15083479
[TBL] [Abstract][Full Text] [Related]
11. Statistical issues in interpreting clinical trials.
DeMets DL
J Intern Med; 2004 May; 255(5):529-37. PubMed ID: 15078496
[TBL] [Abstract][Full Text] [Related]
12. Bayesian estimation of cost-effectiveness from censored data.
Heitjan DF; Kim CY; Li H
Stat Med; 2004 Apr; 23(8):1297-309. PubMed ID: 15083484
[TBL] [Abstract][Full Text] [Related]
13. Non-inferiority study design: lessons to be learned from cardiovascular trials.
Head SJ; Kaul S; Bogers AJ; Kappetein AP
Eur Heart J; 2012 Jun; 33(11):1318-24. PubMed ID: 22564354
[TBL] [Abstract][Full Text] [Related]
14. The value of clinical wisdom in randomised studies, real-world registries and new hypotheses.
Bernardi G; Morocutti G; Spedicato L; Zanuttini D
J Cardiovasc Med (Hagerstown); 2007 May; 8(5):313-7. PubMed ID: 17443094
[No Abstract] [Full Text] [Related]
15. Fallacies in clinical cardiovascular trials.
Swedberg K
Heart; 2009 Sep; 95(17):1464-8. PubMed ID: 19684197
[No Abstract] [Full Text] [Related]
16. Re: "use of a Bayesian approach to decide when to stop a therapeutic trial: the case of a chemoprophylaxis trial in human immunodeficiency virus infection".
van Noord PA; van der Tweel I
Am J Epidemiol; 2005 Nov; 162(10):1033-5. PubMed ID: 16221807
[No Abstract] [Full Text] [Related]
17. Cardiovascular clinical trials in Japan and controversies regarding prospective randomized open-label blinded end-point design.
Kohro T; Yamazaki T
Hypertens Res; 2009 Feb; 32(2):109-14. PubMed ID: 19262468
[TBL] [Abstract][Full Text] [Related]
18. Trials and tribulations of noninferiority: the ximelagatran experience.
Albers GW; Diener HC; Frison L; Grind M; Horrow J; Nevinson M; Olsson SB; Partridge S; Petersen P; Vahanian A; Halperin JL;
J Am Coll Cardiol; 2006 Sep; 48(5):1058; author reply 1059. PubMed ID: 16949503
[No Abstract] [Full Text] [Related]
19. Three-arm noninferiority trials with a prespecified margin for inference of the difference in the proportions of binary endpoints.
Hida E; Tango T
J Biopharm Stat; 2013; 23(4):774-89. PubMed ID: 23799810
[TBL] [Abstract][Full Text] [Related]
20. On the design and analysis of randomized clinical trials with multiple endpoints.
Tang DI; Geller NL; Pocock SJ
Biometrics; 1993 Mar; 49(1):23-30. PubMed ID: 8513104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
